Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-7108 in Healthy Adults and Exocrine Pancreatic Insufficiency
NCT05082051Phase 1Completed
- Sponsor
- Nestlé
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing CDX-7108 with Placebo (2 arms). Primary endpoints: Adverse events up to 9 weeks, Changes in haematology from baseline up to 5 weeks and 6 more. Started Oct 2021; status: completed.
02
Drugs
CDX-7108
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT05082051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082051.